Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Current Assets (2021 - 2025)

Verrica Pharmaceuticals has reported Current Assets over the past 5 years, most recently at $42.5 million for Q4 2025.

  • Quarterly results put Current Assets at $42.5 million for Q4 2025, down 16.88% from a year ago — trailing twelve months through Dec 2025 was $42.5 million (down 16.88% YoY), and the annual figure for FY2025 was $42.5 million, down 16.88%.
  • Current Assets for Q4 2025 was $42.5 million at Verrica Pharmaceuticals, up from $36.3 million in the prior quarter.
  • Over the last five years, Current Assets for VRCA hit a ceiling of $102.0 million in Q1 2021 and a floor of $28.2 million in Q3 2024.
  • Median Current Assets over the past 5 years was $57.1 million (2022), compared with a mean of $59.5 million.
  • Biggest five-year swings in Current Assets: soared 111.37% in 2023 and later plummeted 69.27% in 2024.
  • Verrica Pharmaceuticals' Current Assets stood at $74.3 million in 2021, then crashed by 47.38% to $39.1 million in 2022, then skyrocketed by 98.21% to $77.5 million in 2023, then crashed by 33.99% to $51.2 million in 2024, then fell by 16.88% to $42.5 million in 2025.
  • The last three reported values for Current Assets were $42.5 million (Q4 2025), $36.3 million (Q3 2025), and $36.8 million (Q2 2025) per Business Quant data.